UROV News and Press, Urovant Sciences Ltd. From 12/09/20

WeissLaw LLP Reminds UROV, NAV, PNM, and MVC Shareholders About Its Ongoing Investigations NEW YORK , Dec. 9, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questi...

WeissLaw LLP Reminds CCR, TCO, UROV, and PTI Shareholders About Its Ongoing Investigations PR Newswire NEW YORK, Nov. 30, 2020 NEW YORK , Nov. 30, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would like...

Urovant Sciences (UROV) reports topline data from the Phase 2a trial evaluating once-daily vibegron 75 mg in women with abdominal pain due to irritable bowel syndrome ((IBS)) with IBS-D (diarrhea) and IBS-M (mixed IBS). A total of 222 female IBS patients were enrolled, 189 of whom completed t...

Key secondary endpoint of Global Improvement Scale (GIS) showed numerical differences in favor of vibegron versus placebo, however data was not statistically significant Vibegron was generally well-tolerated with safety profile comparable to placebo Urovant Sciences ...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadThe week ahead will see investors once again weigh the brightening prospects for COVID-19 vaccines against a surging pand...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

NEW YORK, NY / ACCESSWIRE / November 20, 2020 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: HD Supply Holdings, Inc. (NASDAQ:HDS) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. A ho...

Urovant Sciences (UROV) has announced efficacy and safety data from EMPOWUR long term extension study evaluating vibegron for the treatment of overactive bladder ((OAB)).Results from the 40-week EMPOWUR extension to the 12-week trial showed, 75 mg of vibegron was well tole...

Extension study demonstrates favorable results in long term treatment of overactive bladder with vibegron, including improvements in incontinence efficacy, quality of life endpoints and with good tolerability Long term EMPOWUR extension study data featured in an oral presentat...